Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Lee, Sangheun ^a   Kim, Beom Kyung ^a   Kim, Seung Up ^a,b   Park, Yehyun ^a   Chang, Sooyun ^a   Park, Jun Yong ^a,b   Kim, Do Young ^a,b   Ahn, Sang Hoon ^a,b,c   Chon, Chae Yoon ^a,b   Han, Kwang Hyub ^a,b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Center   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SKIN REACTION; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LOCAL THERAPY; LOCOREGIONAL TREATMENT; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; TUMOR VOLUME;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84885393850     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077240     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108. doi:10.3322/canjclin.55.2.74. PubMed: 15761078.
2. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917. doi:10.1016/S0140-6736(03)14964-1. PubMed: 14667750.
3. Bruix J, Sherman M, (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236. doi:10.1002/hep.20933. PubMed: 16250051.
4. Lencioni R, Crocetti L, (2012) Local-regional treatment of hepatocellular carcinoma. Radiology 262: 43-58. doi:10.1148/radiol.11110144. PubMed: 22190656.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390. doi:10.1056/NEJMoa0708857. PubMed: 18650514.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34. doi:10.1016/S1470-2045(08)70285-7. PubMed: 19095497.
7. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109. doi:10.1158/0008-5472.CAN-04-1443. PubMed: 15466206.
8. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, et al. (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59: 561-574. doi:10.1007/s00280-006-0393-4. PubMed: 17160391.
9. Kim BK, Kang WJ, Kim JK, Seong J, Park JY, et al. (2011) (18) F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 117: 4779-4787. doi:10.1002/cncr.26099. PubMed: 21469082.
10. Kim HY, Park JW, Nam BH, Kim HK, Choi JI, et al. (2011) Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol 26: 1612-1618. doi:10.1111/j.1440-1746.2011.06751.x. PubMed: 21517968.
11. Qu XD, Chen CS, Wang JH, Yan ZP, Chen JM, et al. (2012) The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer 12: 263. doi:10.1186/1471-2407-12-263. PubMed: 22721173.
12. Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, et al. (2012) Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys 82: 2004-2011. doi:10.1016/j.ijrobp.2011.03.019. PubMed: 21621346.
13. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, et al. (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103: 914-921. doi:10.1111/j.1572-0241.2007.01712.x. PubMed: 18177453.
14. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, et al. (2008) Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 49: 523-529. doi:10.1080/02841850801958890. PubMed: 18568538.
15. Yoo DJ, Kim KM, Jin YJ, Shim JH, Ko GY, et al. (2011) Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol 26: 145-154. doi:10.1111/j.1440-1746.2010.06341.x. PubMed: 21175808.
16. Lee JM, Han KH, (2010) Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective. Oncology 78: 167-171. doi:10.1159/000315246. PubMed: 20616600.
17. Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, et al. (2011) The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 34: 205-213. doi:10.1111/j.1365-2036.2011.04697.x. PubMed: 21605146.
18. Park JW, Koh YH, Kim HB, Kim HY, An S, et al. (2012) Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 56: 1336-1342. doi:10.1016/j.jhep.2012.01.006. PubMed: 22314421.
19. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, et al. (2011) Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29: 3960-3967. doi:10.1200/JCO.2011.37.1021. PubMed: 21911714.
20. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, et al. (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47: 2117-2127. doi:10.1016/j.ejca.2011.05.007. PubMed: 21664811.
21. Liver Korean, Cancer Study Group and National Cancer Center (2009) Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 15: 391-423. doi:10.3350/kjhep.2009.15.3.391. PubMed: 19783891.
22. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, et al. (2008) Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 113: 995-1003. doi:10.1002/cncr.23684. PubMed: 18615601.
23. Aaltonen T, Adelman J, Akimoto T, Albrow MG, González BA, et al. (2008) Forward-backward asymmetry in top-quark production in pp[over] collisions at sqrt[s]=1.96 TeV. Phys Rev Lett 101: 202001. doi:10.1103/PhysRevLett.101.202001. PubMed: 19113329.
24. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, et al. (2007) Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 110: 129-137. doi:10.1002/cncr.22759. PubMed: 17508408.
25. Seong J, Lee IJ, Shim SJ, Lim do H, Kim TH, et al. (2009) A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int 29: 147-152. doi:10.1111/j.1478-3231.2008.01873.x. PubMed: 18795897.
26. Kim JK, Han KH, Lee JT, Paik YH, Ahn SH, et al. (2006) Long-term clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166/chitosan complex (Milican) for the treatment of small hepatocellular carcinoma. Clin Cancer Res 12: 543-548. doi:10.1158/1078-0432.CCR-05-1730. PubMed: 16428498.
27. Koom WS, Seong J, Han KH, Lee do Y, Lee JT, (2010) Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas? Int J Radiat Oncol Biol Phys 77: 1433-1440. doi:10.1016/j.ijrobp.2009.07.1676. PubMed: 19896779.
28. Lipworth AD, Robert C, Zhu AX, (2009) Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77: 257-271. doi:10.1159/000258880. PubMed: 19923864.
29. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, et al. (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol 57: 821-829. doi:10.1016/j.jhep.2012.06.014. PubMed: 22727733.
30. Di Costanzo GG, Tortora R, Iodice L, Lanza AG, Lampasi F, et al. (2012) Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. Dig Liver Dis 44: 788-792. doi:10.1016/j.dld.2012.04.001. PubMed: 22579445.
31. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X, (2004) Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 10: 2878-2882. PubMed: 15334691.
32. Jiang H, Meng Q, Tan H, Pan S, Sun B, et al. (2007) Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer 121: 416-424. doi:10.1002/ijc.22655. PubMed: 17330237.
33. Sieghart W, Pinter M, Reisegger M, Müller C, Ba-Ssalamah A, et al. (2012) Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. Eur Radiol 22: 1214-1223. doi:10.1007/s00330-011-2368-z. PubMed: 22215073.
34. Cheng JC, Chou CH, Kuo ML, Hsieh CY, (2006) Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25: 7009-7018. doi:10.1038/sj.onc.1209706. PubMed: 16732316.
35. Chung YL, Jian JJ, Cheng SH, Tsai SY, Chuang VP, et al. (2006) Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res 12: 2706-2715. doi:10.1158/1078-0432.CCR-05-2721. PubMed: 16675562.
36. Ma BB, Bristow RG, Kim J, Siu LL, (2003) Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 21: 2760-2776. doi:10.1200/JCO.2003.10.044. PubMed: 12860956.
37. Cao C, Albert JM, Geng L, Ivy PS, Sandler A, et al. (2006) Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res 66: 11409-11415. doi:10.1158/0008-5472.CAN-06-2414. PubMed: 17145887.
38. Kim BK, Park JY, Choi HJ, Kim do Y, Ahn SH, et al. (2011) Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 137: 659-667. doi:10.1007/s00432-010-0917-5. PubMed: 20552225.
39. Kim BK, Ahn SH, Seong JS, Park JY, Kim do Y, et al. (2011) Early alpha-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int 31: 369-376. doi:10.1111/j.1478-3231.2010.02368.x. PubMed: 21083802.